TherapeuticsMD (TXMD) Stock Price, News & Analysis

Company Overview

TherapeuticsMD, Inc. (NASDAQ:TXMD) is a women's healthcare company dedicated to the development and commercialization of hormone therapy and contraceptive products. The company’s primary focus lies in addressing unmet needs in menopause management and birth control by offering innovative, non-estrogen alternatives designed to improve patient convenience and adherence. TherapeuticsMD operates in the United States, serving women through a specialty care distribution network that includes physician practices, clinics and pharmacies.

Among its flagship products is IMVEXXY, an FDA-approved low-dose vaginal estradiol insert indicated for the treatment of moderate to severe dyspareunia due to menopause. The company also markets BIJUVA, the first combination bio-identical estrogen and progesterone capsule for the treatment of moderate to severe hot flashes. In addition, TherapeuticsMD is advancing a pipeline of novel contraceptive technologies, including transdermal delivery systems and oral formulations aimed at providing more flexible dosing options.

Founded in 2015 and headquartered in Boca Raton, Florida, TherapeuticsMD has built a leadership team with extensive experience in women’s health and specialty pharmaceuticals. The organization emphasizes strategic partnerships and targeted clinical development to support product launches and lifecycle management. With a commitment to research and patient-centric care, TherapeuticsMD continues to expand its portfolio and strengthen its position in the women’s health market.

Key Stats

• Today's Range: $1.03 to $1.04
• 50-Day Range: $1.04 to $1.17
• 52-Week Range: $0.70 to $2.44
• Volume: 8,826 shs
• Average Volume: 198,226 shs
• Market Capitalization: $12.03 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

TherapeuticsMD Stock Analysis - MarketRank™

TherapeuticsMD scored higher than 12% of companies evaluated by MarketBeat, and ranked 905th out of 942 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for TherapeuticsMD.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Book Value per Share Ratio

TherapeuticsMD has a P/B Ratio of 0.43. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.34% of the float of TherapeuticsMD has been sold short.

Short Interest Ratio / Days to Cover

TherapeuticsMD has a short interest ratio ("days to cover") of 1.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in TherapeuticsMD has recently increased by 93.50%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

TherapeuticsMD does not currently pay a dividend.

Dividend Growth

TherapeuticsMD does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.34% of the float of TherapeuticsMD has been sold short.

Short Interest Ratio / Days to Cover

TherapeuticsMD has a short interest ratio ("days to cover") of 1.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in TherapeuticsMD has recently increased by 93.50%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 3.3 / 5
• News Sentiment: 0.95

News Sentiment

TherapeuticsMD has a news sentiment score of 0.95. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.75 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for TherapeuticsMD this week, compared to 0 articles on an average week.

MarketBeat Follows

5 people have added TherapeuticsMD to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, TherapeuticsMD insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 2.30% of the stock of TherapeuticsMD is held by insiders.

Percentage Held by Institutions

Only 30.74% of the stock of TherapeuticsMD is held by institutions.

TXMD Stock Analysis - Frequently Asked Questions

How have TXMD shares performed this year?

TherapeuticsMD's stock was trading at $0.86 at the beginning of the year. Since then, TXMD shares have increased by 19.2% and is now trading at $1.0250.

How were TherapeuticsMD's earnings last quarter?

TherapeuticsMD, Inc. (NASDAQ:TXMD) posted its earnings results on Tuesday, August, 12th. The company reported $0.05 earnings per share (EPS) for the quarter. The business had revenue of $0.95 million for the quarter. TherapeuticsMD had a negative net margin of 17.94% and a negative trailing twelve-month return on equity of 2.01%.

When did TherapeuticsMD's stock split?

Shares of TherapeuticsMD reverse split on Monday, May 9th 2022.The 1-50 reverse split was announced on Monday, May 9th 2022. The number of shares owned by shareholders was adjusted after the market closes on Monday, May 9th 2022. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.

How do I buy shares of TherapeuticsMD?

Shares of TXMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of TherapeuticsMD own?

Based on aggregate information from My MarketBeat watchlists, some other companies that TherapeuticsMD investors own include Voyager Therapeutics (VYGR), Humana (HUM), American Water Works (AWK), Waste Connections (WCN), Marinus Pharmaceuticals (MRNS), AUO (AUOTY) and The RMR Group (RMR).

Company Calendar

• Last Earnings: 8/12/2025
• Today: 10/14/2025
• Next Earnings (Estimated): 11/11/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:TXMD
• Previous Symbol: NYSEMKT:TXMD
• CIK: 25743
• Web: www.therapeuticsmd.com
• Phone: (561) 961-1900
• Fax: 561-431-3389
• Employees: 420
• Year Founded: 2008

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$2.18 million
• Net Margins: -17.94%
• Pretax Margin: -23.72%
• Return on Equity: -2.01%
• Return on Assets: -1.40%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.89
• Quick Ratio: 2.89

Sales & Book Value

• Annual Sales: $1.76 million
• Price / Sales: 6.74
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.37 per share
• Price / Book: 0.43

Miscellaneous

• Outstanding Shares: 11,570,000
• Free Float: 11,308,000
• Market Cap: $11.86 million
• Optionable: Optionable
• Beta: 0.58